As Biogen Prepares to Reveal Alzheimer's Data, Expectations Are High

CAMBRIDGE, Mass. (TheStreet) -- Researchers on behalf of Biogen Idec  on Friday will present detailed results for the first time from an early-stage study of the company's experimental drug BIIB037 in patients with the mildest forms of Alzheimer's disease. Friday's presentation is important because it will fill in key details about BIIB037 that were left unanswered last December, when Biogen first told investors the drug demonstrated a statistically significant reduction in amyloid levels and ...